BIOCAD expands into European markets through partnership in Finland


Biotechnological company BIOCAD expands internationally. The company plans to enter European market through partnership in Finland. This partner program covers collaboration in education, fundamental sciences and commercial manufacturing. Total investment over 7 years will exceed 25 million euro.

The first European facility and mutual scientific projects will be located in the region of Southwest Finland – Turku. Such decision was supported by the University of Turku, Abo Academi University and Turku Science Park Ltd. Besides leading educational organizations in life sciences, here is located one of the main biopharmaceutical cluster in EU.  On the 23 of May 2017, the general partnership agreement was signed as a part of Russia-Finland congress. In the nearest future, the mutual collaboration will cover medicine and business development.

MAS at five: Biofem, Sproxil celebrate

 BIOCAD expands into Europe

Mayor of Turku city – Alexi Randell supported the new European facility in Turku: «The localization of BIOCAD in the city will strengthen our positions as a leading region in life sciences in Finland. Currently Turku makes over half of turnover of pharmaceutical products in Finland. The new facility of Russian company BIOCAD in our city will turn it into the main pharmaceutical center in Finland»

The CEO of BIOCAD – Dmitry Morozov announced: “The main goal of our presence in Turku is mutual collaboration in scientific projects and research in immune-oncology field. BIOCAD covers this area for the long time and will be focused on further development of innovative molecules for the EU”

Tuberculosis Deaths Rising Again in Europe, Says WHO

According to the speech of the Rector of the University of Turku – Kalervo Väänänen: «The medicine development is one of the key competence of the university. The announcement of BIOCAD intensions regarding new production facility in Turku made us very happy. The scientific community of Turku is ready for mutual collaboration. The local educational organization will provide all the necessary human resources to secure all the emerging working places».

At this stage, BIOCAD has already developed seven molecules for the European markets, which are used in treatment of oncologic and autoimmune diseases such as melanoma, breast cancer, gastric cancer, kidney cancer, lung cancer, rheumatoid arthritis, and multiple sclerosis, which are very problematic therapeutic areas for Baltic region.

BIOCAD Registers the First Rituximab Biosimilar in Bolivia and Honduras

The company creates the new technological working places for the students graduated from the University of Turku. The HR policy of BIOCAD covers collaboration in education and development of young talents.

BIOCAD sees high perspectives in mutual collaboration program covering unmet medical needs of patients.



Please enter your comment!
Please enter your name here